GANX

Gain Therapeutics, Inc. [GANX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GANX Stock Summary

Top 10 Correlated ETFs

GANX


Top 10 Correlated Stocks

GANX


In the News

02:30 28 Mar 2024 GANX

Gain Therapeutics to Present at Public Ventures Discovery Day

Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr. Gain Therapeutics' Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr.

01:01 28 Mar 2024 GANX

Gain Therapeutics, Inc. (GANX) Upgraded to Strong Buy: Here's What You Should Know

Gain Therapeutics, Inc. (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

05:56 28 Mar 2024 GANX

Doubling Down On Gain Therapeutics

The biotech bear market has presented investment opportunities for investors to take meaningful stakes of public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success using its physics-based approach to finding allosteric binding sites on proteins. Recent investment activity and biopharma deals have reduced financial risks for Gain Therapeutics and provided additional valuation comparisons.

11:17 28 Mar 2024 GANX

Bears are Losing Control Over Gain Therapeutics, Inc. (GANX), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics, Inc. (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

01:32 28 Mar 2024 GANX

Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock

Gain Therapeutics (GANX) to issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $9.4 million in gross proceeds from this issue.

08:45 28 Mar 2024 GANX

Why Is Gain Therapeutics (GANX) Stock Moving Today?

Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a press release from Gain Therapeutics, the company has started dosing the first two subjects in its Phase 1 clinical trial.

04:05 28 Mar 2024 GANX

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company's Chief Executive Officer, Matthias Alder, will participate in a fireside chat and host one-on-one meetings at Cantor Fitzgerald Global Healthcare Conference taking place in New York, NY, September 26-28, 2023.

04:05 28 Mar 2024 GANX

Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference

BETHESDA, Md., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer of Gain Therapeutics, will deliver a featured presentation at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference: Drug Discovery for Progressive Central Nervous System Disorders. The event is taking place at the Sheraton Boston in Boston, Massachusetts, between September 26-27, 2023.

10:01 28 Mar 2024 GANX

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates

Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.

08:00 28 Mar 2024 GANX

Gain Therapeutics to Present at the Jefferies Healthcare Conference

BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will present at the Jefferies Healthcare Conference, taking place June 7-9 in New York, NY.